TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00170612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: 23-valent PPS, 25 micrograms/serotype

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: 23-valent PPS, 25 micrograms/serotype

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: 23-valent PPS, 25 micrograms/serotype

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: 23-valent PPS, 25 micrograms/serotype

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: 23-valent PPS, 25 micrograms/serotype

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: 23-valent PPS, 25 micrograms/serotype

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: 23-valent PPS, 25 micrograms/serotype

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax 23
Description: 23-valent PPS, 25 micrograms/serotype

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype
Study: NCT01798992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate + doxazosin
Study: NCT00495404

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physician Treatment Guidelines

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physician Treatment Guidelines
Study: NCT02461030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In-office and at home Colgate sensitive pro-relief - CSPR
Description: Prophylaxis with rubber cup using In-office Colgate sensitive pro-relief (CSPR), after non-surgical periodontal therapy, and tooth brushing with at home CSPR toothpaste.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: In-office Villevie® prophy paste + Colgate Toothpaste
Description: Prophylaxis with rubber cup using In-office Villevie® (fluoride-free) prophy paste + Colgate Toothpaste, after non-surgical periodontal therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Full-mouth debridment, scaling and root planing with ultrasonic/hand instruments

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Full-mouth debridment, scaling and root planing with ultrasonic/hand instruments
Study: NCT04047797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given by mouth

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given Intravenous
Study: NCT01480284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK548470 300 mg tablet
Description: Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETV 0.5 mg capsule
Description: Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
Study: NCT05053477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mehylprednisolone injection
Description: (40 mg)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency (PRF)
Description: . PRF lesion will be carried out for 120 seconds at a 2 Hz frequency and pulse width of 20 ms at 42°C

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich plasma
Description: 2 ml of PRP
Study: NCT04236648

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally-invasive non-surgical therapy (MINST)
Description: subgingival root debridement with a minimally-invasive approach using piezoelectric/ultrasonic instruments
Study: NCT01383096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 800mg Powder in Bottle for Oral Suspension
Description: OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OZ439 mesylate 800mg Powder in Bottle for Oral Suspension
Description: OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 800mg Powder in Bottle for Oral Suspension
Description: OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 800mg Powder in Bottle for Oral Suspension
Description: OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 800mg Powder in Bottle for Oral Suspension
Description: OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 400mg Prototype Solution Formula 1
Description: OZ439 400 mg (as free base) as a prototype solution formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 800mg Prototype Solution Formula 1
Description: OZ439 800 mg (as free base) as a prototype solution formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 800mg Prototype Solution Formula 1
Description: OZ439 800 mg (as free base) as a prototype solution formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 800mg Prototype Solution Formula 1
Description: OZ439 800 mg (as free base) as a prototype solution formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 800mg Prototype Solution Formula 2
Description: OZ439 800 mg (as free base) as a prototype solution formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 mesylate 800mg Prototype Solution Formula 2
Description: OZ439 800 mg (as free base) as a prototype solution formulation 2
Study: NCT00820976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Filgrastim(5 µg/kg intravenously over 30 minutes ) was administered starting from day 8 until neutrophil recovery
Study: NCT02869555

Intervention type: OTHER
Intervention: Data collection
Study: NCT03025399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tangwang prescription
Description: A kind of Granule(Tangwang prescription) was composition by five Chinese herbal medicines, every bag has 4.87g granules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a simulated drug of tangwang prescription,included weight, appearance, colour, taste,smell and solubility.
Study: NCT02243098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
Study: NCT00987688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: exposure: Early and sustained hypothermia. Hypothermia will initially be induced by infusion of up to 2L ice cold saline. Following a safety assessment the patient will be rapidly cooled to 33C using surface temperature control equipment. They will be maintained at 33C for 72 hours. Rewarming will occur at a rate of 1C/4hrs and will be titrated to intracranial pressure (ICP) control and BP.
Study: NCT01762670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GoldenCare
Description: Copper intravaginal device to treat bacterial vaginosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 500 mg twice daily for 7 days
Study: NCT02275585

Intervention type: OTHER
Intervention: Event of portal vein thrombosis
Description: There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis
Study: NCT02841228

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT + SIB + Chemotherapy
Description: For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction , SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
Study: NCT03355313

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level Light therapy
Description: Laser will be administered for 10 seconds on four intraoral points and four extraoral points in the region of the parotid glands bilaterally as well as one intraoral point and one extraoral point in the regions of the submandibular and sublingual glands.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level Light therapy
Description: Laser will be administered for 10 seconds on four intraoral points and four extraoral points in the region of the parotid glands bilaterally as well as one intraoral point and one extraoral point in the regions of the submandibular and sublingual glands.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level Light therapy
Description: Laser will be administered for 10 seconds on four intraoral points and four extraoral points in the region of the parotid glands bilaterally as well as one intraoral point and one extraoral point in the regions of the submandibular and sublingual glands.
Study: NCT00648089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO
Description: Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
Study: NCT04157504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical function assessment
Description: Physical function assessment is a tool to evaluate mobility levels of patients
Study: NCT02627222

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pro-vitamin A biofortified cassava
Description: Pro-vitamin A biofortified cassava is the product of international conventional breeding programs (non-GMO) in order to increase the pro-vitamin A content of cassava for improved nutritional intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White cassava
Description: Conventional white cassava
Study: NCT01423812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twice-daily combination Darunavir and ritonavir
Description: Subjects randomized 1:1 to remain on regimens containing combination Darunavir 600mg plus Ritonavir 100mg twice-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once-daily combination Darunavir and ritonavir
Description: Subjects randomized 1:1 to switch to from combination Darunavir 600mg plus Ritonavir 100mg twice-daily at baseline to the experimental combination Darunavir 800mg plus Ritonavir 100mg once-daily for 48 weeks
Study: NCT02700243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants receive a Fitbit and are followed over the course of one year to determine use and health outcomes.
Study: NCT03366493

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FRD
Description: The Folate Receptor-Mediated Staining Solution is a dye solution that stains for medical purposes used in staining cells and tissues for detecting neoplastic diseases. After inserting a speculum into your vagina, the FRD™ staining solution will be applied to the cervix using an applicator. After removal of the applicator, the doctor will inspect the applicator for color changes and note any changes. The physician will then remove any excess stain from the cervix using distilled water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology
Description: Cytology testing done by collecting samples of cells, and smearing those samples across a glass microscope slide in order to detect abnormal cells that may develop into cervical cancer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPV testing
Description: HPV tests will detect HPV infections, which can lead to cervical cells to become cancer cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: During the colposcopic examination, the physician will insert a speculum into the vagina and then apply a vinegar solution to the cervix. The vinegar solution causes any potential abnormal cells to turn white. These white regions are best seen using the colposcope, which magnifiesthe skin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECC
Description: If the examination is not satisfactory and the doctor is not able to see the entire cervix, he may perform an endocervical curettage, or ECC. This sample is collected by placing a long, thin instrument into the cervical canal and a sample is scraped from that area. The sample will be sent to the laboratory for a pathologist to review.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospy
Description: According to the colposcopy assessment, if the doctor sees a white area, or an area of abnormal cells, a tiny sample of tissue, called a biopsy will be taken from the cervix. About half of women do not feel the biopsy being taken.~Others may feel a quick pinch. After the biopsy, the wound will be treated to stop bleeding.The biopsy will be sent to the laboratory for a pathologist to review.
Study: NCT01978795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain 101 website
Description: Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. Consistent with the literature on effective school-based change efforts, the website offers a comprehensive, school-wide approach to preventing and managing sports concussion, including training for educators, athletics staff, students, and parents. The website presents guidelines for creating a concussion management team (CMT) that meets regularly to support students as they return to academics, extra-curricular activities, and athletics. It also includes information on strategies for supporting students in the classroom following concussion (e.g., designing reduced school schedules, monitoring school performance following concussion).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: At control schools, parents viewed Centers for Disease Control materials on safe teen drivers. Athletes viewed web-based materials about teens staying safe on the job.
Study: NCT00596934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metreleptin
Description: 0.1 mg/kg/day once a day via subcutaneous injections
Study: NCT01690897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based treatment
Description: The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy. In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sex therapy, education, and support treatment
Description: The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.
Study: NCT04065776

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal-avoidance proton therapy
Description: Hippocampal-avoidance proton therapy
Study: NCT03878472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: The patients will received S1 (50 mg/m2, po, bid, d1-d10) every two weeks and be accessed for operational suitability every two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: The patients will received S1 (50 mg/m2, po, bid, d1-d10) every two weeks and be accessed for operational suitability every two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: The patients will receive at least two cycles of oxaliplatin (85 mg/m2 d1) every two weeks and be accessed for operational suitability every two cycles.
Study: NCT03001128

Intervention type: DRUG
Intervention: Antiretroviral treatment pause
Description: Antiretroviral treatment pause

Intervention type: DRUG
Intervention: Antiretroviral treatment pause
Description: Antiretroviral treatment pause
Study: NCT04341896

Intervention type: OTHER
Intervention: Caregivers
Description: Individuals who cared for themselves and their transplant recipient before and after kidney donation

Intervention type: OTHER
Intervention: Non-caregivers
Description: Individuals who donated a kidney as a living donor but did not serve as the primary caregiver for their recipient
Study: NCT01309230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™
Description: Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
Study: NCT04011228

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: After a fasting period over night blood samples will be taken.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: After a fasting period over night blood samples will be taken.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: After a fasting period over night blood samples will be taken.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: After a fasting period over night blood samples will be taken.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: After a fasting period over night blood samples will be taken.

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva and blood samples
Description: After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva and blood samples
Description: After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva and blood samples
Description: After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva and blood samples
Description: After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva and blood samples
Description: After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnet Resonance Spectroscopy
Description: The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnet Resonance Spectroscopy
Description: The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnet Resonance Spectroscopy
Description: The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnet Resonance Spectroscopy
Description: The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnet Resonance Spectroscopy
Description: The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.
Study: NCT02308007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terconazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terconazole/metronidazole